Analysis of Kiran Mazumdar Shaw

vAs an Entrepreneur:
ØStarted business with just Rs 10000/- and degree in brewery. ØShe became an Entrepreneur by accident. ØBanks refused her loan due to lack of assets. ØBiotechnology industry was a new field in India.

Personality Traits
vDetermination
Øshe was determined to build up Biocon.

vConfidence
ØStarted business in relatively new innovative field ØHer confidence is commendable when comparing with the challenges that she has faced

vMotivation
ØEmployee feedbacks. ØPerformance checks. ØWork place principles.

vSocially Responsible
ØThe Biocon Foundation in 2004, setup “Arogya Raksha Yojana”. Øcity improvement programs like the Bangalore Agenda Task Force (BATF).
 

vRisk Taker
Ø Beacon’s R&D programme was rapidly advanced Ø Took the risk to produce Oral Insulin an Anti - CD6 Monoclonal antibody

vInnovative
vEg:
Ø INSUGEN R Ø BIOMAB-EGFR Ø RAPACAN

Achievements of kiran Mazumdar shaw
vShe is in the list of 100 most powerful women (by Forbes, 2010) vNikkei Asia Prizes- Regional Growth by Nikkei Inc. (2009) vExpress pharmaceutical leadership summit award for dynamic entrepreneur (2009) vBusinesswomen of the year by Economic Times (2009) vHonorary Doctorate from university of Abertay Dundee UK.(2007)

vWharton Infosys Business transformation Award (2006) vPadma Bhushan (2005) vHonorary Doctorate from Manipal Academy of Higher education –MAHE (2005) vLife time Achievement Award from Indian chamber of Commerce (2005) vHonorary Doctorate of Science from Ballard University (2004)
 

SUCCESS OF BIOCON
vBiocon India Group story began in 1978. vIn 1989, Unilever acquired 30% stake. vIn 1997, Unilever sold their stake to ICI. vEventually John shaw purchased the entire shareholding from ICI. vIn 1994, Syngene International was established to carry out drug based contract research. vIn 2000, ClinigeneInternational was started to conduct longitudinal clinical studies. v

CONTROVERSIES
vAir and Water pollution in Hebbagodi in Bangalore
ØEffects :
§ De to industrial waste § Dying of fish because of chemical effluents. § People were suffering from skin diseases, headaches, kidney problems.

ØMeasure taken:
§ Hebbagodi residents complained about the contamination § Steps taken to improve quality of water and to reduce the odour §

Ø Allegedly violat certain norms of manufacturing Methylcobalamin
§ Obtained license from the Karnataka government to manufacture the drug in seven stages. § But during inspection found that the company is importing the drug from china. § The state government issues notice to biocon company. § Biocon got the license from the Central government to import Methylcobalamin. § Manufacture the product starting from cyanocobalaminusing a multi-step process.

Awards and Achievements
v 2010: Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector at Bangalore Bio v 2009: - Among Top 20 Indian companies in Forbes ‘Best Under A Billion’ list - Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector at Bangalore Bio - Bio-Excellence Award for outstanding achievement in the Biotech Service Sector at Bangalore Bio for Syngene IDMA ‘Best Patent of the year’ award - BIOMAb EGFR® voted ‘Bio-Spectrum Asia-Pacific Product of the year’, 2008 - BioSingapore Asia Pacific Biotechnology Award for Best Listed Company

v2008: - Ranked among the top 20 global biotechnology companies. - 7th largest biotech employer in the world (Source: Med Ad News, June 2008) v2007: ‘BioServices Company of the Year’ for Syngene, BIOMAb EGFR® wins ‘Product of the Year’, BioSpectrum Awards v2006: Best IT User Award in the Pharmaceutical Sector, NASSCOM. AND MANY MORE.......

FACTS - “FIRSTS”
v First Indian biotech company to receive US funding for proprietary technologies (1989) v Sets up India's first clinical research organization, Clinigene (2000) v First Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule (2001) v First company worldwide to develop human insulin on a Pichia expression system (2003) v Biocon enters the stock market with its IPO and becomes only the second Indian company to cross the $1-billion mark on the day of listing (2004) v Launches India’s first cancer drug, BIOMAb EGFR® (2006) v First Indian company to manufacture and export enzymes to USA and Europe v India’s largest producer and exporter of enzymes v Releases country’s first 24-hour diabetes drug, Glargine (2009) v First biotech company to receive ISO 9001 certification in India v Syngene is country’s first custom research company in drug discovery

Sign up to vote on this title
UsefulNot useful